Red Blood Cell-Derived miR-93-5p Correlates with PD-1/PD-L1 Upregulation and Poor Prognosis in Lung Cancer.

ABSTRACT:

Background

Lung cancer remains the deadliest malignancy. Although PD-1/PD-L1 immune checkpoint inhibitors have improved survival, their benefit is limited by persistent immune resistance. Identifying systemic regulators of tumor immune microenvironment may enhance therapeutic efficacy. We previously showed that RBC-derived miR-93-5p promotes PTEN loss and PI3K-AKT activation. This study examined whether RBC-derived miR-93-5p is associated with immune checkpoint activity and features of T-cell exhaustion in lung cancer.

Methods

RBCs, RBC-derived exosomes, and plasma were isolated from 80 lung cancer patients and 30 controls, and tumor and matched noncancerous lung tissues were collected. miR-93-5p expression was quantified by droplet digital PCR. PD-1, PD-L1, CD8⁺

SUBMITTER: Dhilipkannah P 

PROVIDER: S-EPMC12724151 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature